EntryPoint Capital LLC Has $598,000 Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

EntryPoint Capital LLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 59.5% in the 4th quarter, Holdings Channel reports. The fund owned 2,542 shares of the biopharmaceutical company’s stock after buying an additional 948 shares during the period. EntryPoint Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $598,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $1,045,822,000. Raymond James Financial Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $65,295,000. Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $61,160,000. Proficio Capital Partners LLC grew its position in Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock worth $45,570,000 after acquiring an additional 192,916 shares during the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $41,529,000. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday. Sanford C. Bernstein reduced their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a report on Friday. Royal Bank of Canada increased their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a report on Friday. Finally, Scotiabank lifted their target price on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a report on Friday. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $312.30.

Alnylam Pharmaceuticals Trading Up 2.6 %

Shares of Alnylam Pharmaceuticals stock opened at $290.70 on Tuesday. The stock has a market capitalization of $37.63 billion, a PE ratio of -133.96 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a 50 day moving average price of $257.81 and a two-hundred day moving average price of $260.02. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.